Metabolic and energetic benefits of microRNA-22 inhibition.

Marc ThibonnierChristine EsauSujoy GhoshEdward WargentClaire Stocker

Published in: BMJ open diabetes research & care (2021)

These original findings suggest that microRNA-22-3p inhibition could lead to a potent treatment of fat accumulation, insulin resistance, and related complex metabolic disorders such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease.

Keyphrases

insulin resistance
adipose tissue
metabolic syndrome
high fat diet induced
type diabetes
high fat diet
skeletal muscle
glycemic control
polycystic ovary syndrome
weight loss
cardiovascular risk factors
body mass index
liver fibrosis